All analyses
AI analysis

Maskeliya Plantations Plc: research report

UndervaluedneutralAug 14, 2026

Maskeliya is profitable and cheaply valued, but its latest comparable-basis June margins were the weakest in its three-year June record. The tension is a P/E of 5.24 against a 31.3% one-year price fall.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why balanced

  • Audited FY2025 net profit grew 104.7%, showing a substantial recovery in absolute earnings.
  • Return on equity was 35.6%, while the dividend yield was 6.3%, providing support for the current valuation.
  • The P/E of 5.24 sits at the 4th sector percentile, indicating an unusually low earnings multiple among plantation and agricultural peers.

Against this. The latest June quarter was the worst of three comparable June quarters for gross, operating and net margins, with net margin at 9.3%.

Operating margin
13.8%sector 8.4%
from 15.3% a year earlier
Net margin
9.3%sector 4.3%
from 10.3% a year earlier, revenue -2.6%
Return on equity
20.4%
twelve months to Jun 30, 2026, unaudited
P/E
5.1sector 9.3
earnings Rs 11.83 per share
P/B
1.04sector 1.11
book Rs 57.87 per share
Dividend yield
6.67%sector 2.35%
33.8% of earnings paid out

Current figures, updated daily from filings to Jun 30, 2026. The report below was written on Aug 14, 2026. Sector figures are the median of 25 listed companies in the same sector.

Overview

Maskeliya Plantations is an integrated tea producer with 18 estates and 15 processing centres, supplemented by timber, coffee, cinnamon and fruit cultivation. Its vertically integrated model gives it exposure to both tea production and auction and export markets.

The key change is that profitability has recovered strongly on an audited full-year basis, but the latest quarter shows weaker operating economics than the company's comparable June history. The evidence therefore supports a balanced view rather than a clear directional call.

Price performance

The share has underperformed sharply: at LKR 63.90 on 2026-08-14, it was down 31.3% over one year while the ASPI gained 9.3% over the same period. The three-month fall was 10.0%, compared with a 5.6% decline for the index.

The price sat at only 1.6% of its 52-week range, close to the lower end rather than the middle. Recent annualised volatility was 16.9% below the company's own one-year norm, while 20-day volume was 0.6% below its 60-day average, indicating weak recent trading activity rather than unusually heavy turnover.

Valuation

Maskeliya trades at a P/E of 5.24, ranked at the 4th percentile of the sector, while its P/B of 1.1 is less extreme at the 38th percentile. The 35.6% audited ROE helps explain why the stock is not trading below book value despite its low earnings multiple.

The 6.3% dividend yield ranks at the 88th sector percentile. However, the payout direction is softer: dividend per share moved from LKR 4.5 in FY2025 to LKR 4.0 in FY2026. The latest year's payment may still be incomplete, so this is evidence of a lower current distribution, not proof of a completed multi-year cut.

News and sentiment

Direct coverage is thin, with no material company articles recorded in the latest 90-day window and no sentiment split to interpret. The confirmed FY2026 first interim dividend had an ex-date of 2026-04-10 and payment date of 2026-04-30, so it is already completed rather than an upcoming catalyst.

Financials

The latest quarter to 2026-06-30 generated revenue of LKR 1.66 billion and net profit of LKR 155 million. Gross margin was 17.6%, operating margin 13.8% and net margin 9.3%, but the June 2025 comparison was filed on a group basis rather than the latest company basis, so the margin changes are not like-for-like. The valid substitute is the company's own comparable-basis record: all three latest margins were the worst of three June observations.

The audited year to 2025-03-31 was stronger, with revenue growth of 6.4% and net profit growth of 104.7%. Return on equity reached 35.6%, while owners' equity was LKR 3.12 billion and the share count was 53.95 million. The latest quarter's LKR 73.7 million gap between operating profit and net profit shows that finance costs, tax and other below-the-line items still absorb part of operating earnings.

Risks

The main risk is that accounting profit does not consistently arrive as cash. In the audited year to 2025-03-31, cash conversion was 0.67x, meaning operating cash flow covered only part of operating profit despite the sharp rise in reported earnings.

Financing risk has improved but remains relevant: gearing was 11.3% of owners' equity, interest cover was 13.25x and the current ratio was 1.18. These figures indicate a much stronger balance sheet than the prior year, but only a modest liquidity buffer. At sector level, labour shortages and a tea market where the year-to-date average was lower in US dollars could pressure margins; higher local fuel prices, up about 47%, add another cost risk.

Outlook

As at 2026-08-14, the next event is the filing for the quarter ending 2026-09-30. The exchange timing range is 2026-11-05 to 2027-01-19, and that filing will replace the June figures currently used here.

The next print matters because the latest company-basis June quarter was weak against its own comparable history, while the audited year was materially stronger. Sector tea prices strengthened in July, but the available data cannot establish how much of that movement reached Maskeliya's realised prices or margins. The broader easing in interest-rate conditions may reduce finance pressure, although the company's latest quarter still carried a LKR 73.7 million below-the-line drag.

About this report. Generated on Aug 14, 2026 from market data up to Aug 14, 2026, 0 material news articles over 90 days and financials to Jun 30, 2026. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports